Nebivolol Krka

Nebivolol, the active ingredient in Nebivolol Krka, is a Beta‑blocker (selective β1‑adrenergic antagonist) presented as an oral tablet for oral use. It reduces elevated blood pressure by decreasing heart rate and peripheral vascular resistance, and is indicated for the treatment of hypertension in adult patients.

GNH USA supplies Nebivolol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines across global markets.

Nebivolol is a selective β1‑adrenergic antagonist used primarily in the management of hypertension.

- Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events.

Nebivolol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Fatigue: mild to moderate tiredness reported by patients. - Headache: occasional throbbing pain. - Dizziness: especially on standing. - Bradycardia: slower than normal heart rate. - Nausea: mild gastrointestinal upset. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: heart rate dropping to dangerously low levels. - Atrioventricular block: impaired electrical conduction. - Bronchospasm: difficulty breathing, particularly in asthmatic patients. - Hypotension: marked drop in blood pressure causing faintness. - Allergic reactions: rash, itching, or swelling. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Heart rate monitoring: assess baseline and periodic pulse. - Hepatic impairment: use with caution in severe liver disease. - Asthma or COPD: avoid in patients with active bronchospasm. - Abrupt discontinuation: taper to prevent rebound hypertension. - Renal function: adjust if severe renal insufficiency is present. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other β‑blockers: additive bradycardia and hypotension. - Calcium‑channel blockers (verapamil, diltiazem): enhanced negative chronotropic effect. - Clonidine: may cause severe hypertension if stopped abruptly. - Insulin or oral hypoglycemics: mask hypoglycemia symptoms. - NSAIDs: may reduce antihypertensive effect.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor for excessive blood‑pressure lowering. - Diuretics: watch for electrolyte disturbances. - Antidepressants (SSRIs, SNRIs): possible additive effects on blood pressure. - Antiarrhythmic agents: potential for conduction abnormalities. - CYP2D6 inhibitors (e.g., fluoxetine): may increase nebivolol plasma levels.